Anthropic is pushing Claude into the lab and says it wants to develop medicines of its own, a sharper move than the usual AI vendor pitch of selling tools to scientists and taking a victory lap in the press release.
The company announced Claude Science at its “The Briefing: AI for Science” event earlier this week. Anthropic describes the product as an AI workbench for researchers that brings scattered tools and datasets into a single environment and can generate figures and visualizations.
Anthropic framed the launch around its claim that AI can speed up scientific work and the creation of healthcare interventions. The company also pointed to biotech and pharmaceutical customers already using Claude, according to The Verge.
Then Anthropic went further. Eric Kauderer-Abrams, the company’s head of life sciences, told CNBC that Anthropic plans to work on discovering treatments for neglected diseases.
A vendor becoming a possible rival
The move puts Anthropic in an awkward and interesting spot. It is selling AI software to drug companies while also saying it intends to pursue drug discovery itself. If that plan becomes more than a research ambition, Anthropic could be providing infrastructure to companies that may overlap with its own future work.
Major AI companies have been courting science and pharma customers for a while. OpenAI, Amazon, Google and others have life-sciences tools or platforms, according to The Verge. Anthropic’s plan stands out because it is one of the more direct public statements from a major frontier AI lab that it wants to develop drugs, rather than only supply software to people who do.
The company would be entering a crowded field. The broader AI drug race includes AI-first drug developers such as Insilico, Isomorphic Labs, which spun out of Google DeepMind, biotech startups, and large pharmaceutical companies building or buying AI systems of their own.
Lots of ambition, few mechanics
Anthropic has not said much publicly about how its drug effort will work. At the event, Kauderer-Abrams did not explain what Anthropic would do if it identified promising drug candidates, according to The Verge.
That missing step matters. Drug discovery software can help researchers search chemical or biological space, connect datasets, or prioritize hypotheses. A candidate still has to move through the rest of the development process before it becomes a treatment people can use. Anthropic has not laid out where it plans to stop, partner, license, or carry work forward if Claude Science or related systems produce something useful.
For now, the confirmed facts are narrower than the sales pitch: Anthropic has launched a science workbench, says existing biotech and pharma customers use Claude, and says it wants to discover treatments for neglected diseases. The rest is still a map with the hard parts politely left blank.
This story draws on original reporting from The Verge.
